Patent intelligence · EP
EP 3630112
KOMBINATION AUS REGORAFENIB UND PD-1/PD-L1(2)-INHIBITOREN ZUR BEHANDLUNG VON KREBS
KOMBINATION AUS REGORAFENIB UND PD-1/PD-L1(2)-INHIBITOREN ZUR BEHANDLUNG VON KREBS
Patent details — EP 3630112
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Apr 8, 2020
- Expiration
- Apr 3, 2040
- Applicant
- BAYER AG [DE]
- CPC classes
- A61K 31/ 44 A I, A61K 31/ 395 A I, A61K 45/ 06 A I, A61K/31395
Quick answer
EP 3630112 (KOMBINATION AUS REGORAFENIB UND PD-1/PD-L1(2)-INHIBITOREN ZUR BEHANDLUNG VON KREBS) is held by BAYER AG [DE]. Status: granted. Granted Apr 8, 2020. Expires Apr 3, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BAYER AG [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 44 A I, A61K 31/ 395 A I, A61K 45/ 06 A I, A61K/31395, A61K/3144, A61K/314412
More from BAYER AG [DE]
Related pharmaceutical patents in our USPTO index.
-
WO 2024052517
USAGE MÉDICAL D'ANTICORPS ANTI-CCR8 ET PROGRAMME DE DOSAGE
granted -
CN 117186084
Pranlerivir sulfonate, and pharmaceutical preparation, preparation method and application thereof in treatment of herpes virus
granted -
CN 115348859
Ophthalmic formulations comprising n-[5-(aminosulfonyl)-4-methyl-1, 3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl) phenyl] acetamide hemihydrate
granted -
CN 115003329
Parapoxvirus for conditioning and treating coronavirus infections
granted -
BR 112021015776
Edição de gene para hemofilia a com expressão de fator viii melhorada
granted -
WO 2021152186
ANTICORPS CCR8 POUR APPLICATIONS THÉRAPEUTIQUES
granted -
DE 102019218587
Kontrastmittelbasierte Gefäßdarstellung
granted -
DE 102019218589
Simultane Bilddarstellung von zwei unterschiedlichen funktionellen Bereichen
granted
Frequently asked questions
What is US patent 3630112?
EP 3630112 (KOMBINATION AUS REGORAFENIB UND PD-1/PD-L1(2)-INHIBITOREN ZUR BEHANDLUNG VON KREBS) is held by BAYER AG [DE]. Status: granted. Granted Apr 8, 2020. Expires Apr 3, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 3630112?
BAYER AG [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does EP 3630112 expire?
Our index shows an expiration date of Apr 3, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.